Publications by authors named "Fidel David Huitzil-Melendez"
Article Synopsis
- The study assessed 5-year survival rates for colorectal cancer patients in Mexico who were treated under Seguro Popular, a public health insurance system.
- It involved 1418 patients diagnosed between 2013 and 2016, revealing an overall survival rate of 50% and noting that 78.1% were diagnosed at advanced stages (III and IV).
- Findings emphasized the importance of early screening, particularly as younger patients with metastatic disease had a poorer prognosis compared to older patients.
Objective: To describe the burden of colorectal cancer (CRC) in Mexico and understand mortality patterns based on sex, geography, and insurance status.
Materials And Methods: Mortality data (1998-2018) from the Instituto Nacional de Estadística y Geografía was obtained. We included colon (C18.
SARS-CoV-2 Infection Rate in Patients With Cancer and Health Care Workers in a Chemoradiotherapy Unit During the Pandemic: A Prospective Cohort in Mexico.
JCO Glob Oncol
September 2021
Article Synopsis
Purpose: The purpose of cancer staging systems is to accurately predict patient prognosis. The outcome of advanced hepatocellular carcinoma (HCC) depends on both the cancer stage and the extent of liver dysfunction. Many staging systems that include both aspects have been developed.
View Article and Find Full Text PDFAdvanced biliary tract carcinomas represent a group of aggressive diseases that still carries a poor prognosis. Chemotherapy has been shown to provide disease control and may also prolong survival. An established role for systemic therapy in the adjuvant setting is still lacking.
View Article and Find Full Text PDFArticle Synopsis
- * Managing HCC effectively requires understanding the role of cirrhosis; traditional methods like the Child-Pugh scoring system have limitations, prompting the development of new scoring systems like CLIP and CUPI that consider cancer-related factors.
- * Despite efforts, traditional chemotherapy has low response rates in HCC, but advancements in targeted therapies like sorafenib show promise for improving survival, highlighting the need for research into optimal dosing and treatment
A 32-year-old Asian male presented with perforated sigmoid colorectal cancer (CRC) and large, unresectable hepatic metastasis. After surgery for his primary tumor, he received 6 months of FOLFOX (5-fluorouracil/leucovorin/ oxaliplatin) plus bevacizumab and achieved a partial response. He underwent hepatic metastasectomy and was found to have had a complete pathologic response (pCR) to treatment.
View Article and Find Full Text PDF